摘要
目的分析消炎利胆片治疗慢性胆囊炎的临床效果。方法106例慢性胆囊炎患者,采用数字随机方法分为研究组和对照组,每组53例。对照组应用头孢曲松钠治疗,研究组在对照组的基础上加用消炎利胆片治疗。比较两组治疗前后胆囊功能指标(胆壁厚度、胆囊收缩率)、炎性因子[肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、白细胞介素-8(IL-8)、白细胞介素-6(IL-6)]水平、中医证候(纳呆腹胀、恶心呕吐、小便赤黄)积分,临床疗效。结果治疗后,两组胆壁厚度小于治疗前、胆囊收缩率高于治疗前,且研究组胆壁厚度(1.85±0.21)mm小于对照组的(2.65±0.38)mm、胆囊收缩率(66.84±7.48)%高于对照组的(50.54±5.47)%,组间差异明显(P<0.05)。治疗后,两组hs-CRP、TNF-α、IL-6、IL-8均低于治疗前,且研究组hs-CRP、TNF-α、IL-6、IL-8分别为(30.12±3.05)mg/L、(3.26±0.34)μg/L、(36.96±5.84)pg/ml、(4.87±1.77)pg/ml,均低于对照组的(38.46±4.17)mg/L、(4.37±1.18)μg/L、(57.29±7.58)pg/ml、(8.25±2.45)pg/ml,组间差异明显(P<0.05)。治疗后,两组纳呆腹胀、恶心呕吐、小便赤黄积分低于治疗前,且研究组纳呆腹胀、恶心呕吐、小便赤黄积分分别为(0.76±0.27)、(0.86±0.22)、(0.80±0.35)分,低于对照组的(1.24±0.45)、(1.13±0.47)、(1.05±0.45)分,组间差异明显(P<0.05)。治疗后,研究组临床总有效率96.23%高于对照组的81.13%,组间差异明显(P<0.05)。结论慢性胆囊炎应用消炎利胆片治疗可帮助患者改善胆囊功能和炎性因子水平,促进临床症状显著减轻,进而提高临床效果。
Objective To analyze the clinical effect of Xiaoyan Lidan tablet in treating chronic cholecystitis.Methods 106 patients with chronic cholecystitis were divided into study group and control group by random numerical table,with 53 cases in each group.The control group was treated with ceftriaxone sodium,and the study group was treated with Xiaoyan Lidan tablet on the basis of the control group.Both groups were compared in terms of gallbladder function indexes gallbladder function indicators(gallbladder wall thickness,gallbladder contraction rate),inflammatory factors[tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP),interleukin-8(IL-8),interleukin-6(IL-6)],traditional Chinese medicine syndrome(anorexia and abdominal distension,nausea and vomiting,deep-coloured urine)scores before and after treatment,and clinical efficacy.Results After treatment,the gallbladder wall thickness was lower than that before treatment,and the gallbladder contraction rate was higher than that before treatment;the gallbladder wall thickness(1.85±0.21)mm in the study group was smaller than(2.65±0.38)mm in the control group,and the gallbladder contraction rate(66.84±7.48)%was higher than(50.54±5.47)%in the control group;the difference between groups was significant(P<0.05).After treatment,hs-CRP,TNF-α,IL-6 and IL-8 in both groups were lower than those before treatment;hs-CRP,TNF-α,IL-6 and IL-8 in the study group were(30.12±3.05)mg/L,(3.26±0.34)μg/L,(36.96±5.84)pg/ml and(4.87±1.77)pg/ml,which were lower than(38.46±4.17)mg/L,(4.37±1.18)μg/L,(57.29±7.58)pg/ml and(8.25±2.45)pg/ml in the control group;the difference between groups was significant(P<0.05).After treatment,the scores of anorexia and abdominal distension,nausea and vomiting,deep-coloured urine in both groups were lower than those before treatment;the anorexia and abdominal distension,nausea and vomiting,deep-coloured urine in the study group were(0.76±0.27),(0.86±0.22)and(0.80±0.35)points,which were lower than(1.24±0.45),(1.13±0.47)and(1.05±0.45)points in the control group;the difference between groups was significant(P<0.05).After treatment,the total clinical effective rate of the study group was 96.23%,which was higher than 81.13%of the control group,and the difference between groups was significant(P<0.05).Conclusion The application of Xiaoyan Lidan tablets in the treatment of chronic cholecystitis can help patients improve gallbladder function and inflammatory factor levels,promote the significant reduction of clinical symptoms,and improve clinical effect.
作者
孔海方
KONG Hai-fang(Department of Surgery,Zhangjiawa Street Community Health Service Center,Laiwu District,Jinan 271100,China)
出处
《中国实用医药》
2025年第11期155-158,共4页
China Practical Medicine
关键词
慢性胆囊炎
消炎利胆片
炎性因子
临床效果
中医证候积分
Chronic cholecystitis
Xiaoyan Lidan tablet
Inflammatory factors
Clinical efficacy
Traditional Chinese medicine syndrome score
